

11. . . . -  
( ) , 2000. - 122 . -
12. . . . -  
// . IV - .-
13. . . . . . -  
- -  
/ . . 6 -  
.414-420. .- ., 1997.-
14. . . . -  
«Hypoxia user» - -  
- -  
// . IV - .-
15. Kuznetsov V.I., Valui V.T., Sachek M.G. On the mechanisms of the positive effect of the interval hypoxic training in treatment of gastric ulcer// Hypoxia medical Journal. - 1998. - N2. - P.89.

• •

« -  
»

.

- , -  
- , -  
- -  
- . -  
- , -  
- 250 . -  
- , -  
- 25 , -  
- [6, 7, 8] -  
- « » -  
- , -  
- : -  
- , -  
- ( -  
- , -  
- , -  
- 3 ( -  
- ). -  
- , -  
- , -  
- ( -  
- ) , -  
- . -  
- ( -  
- ) -  
- 12-24 . -  
- : -  
- , -  
- ; -  
- III-IV , -  
- , -  
- ; -





( 20 40 ), -  
 ( -  
 ) -  
 ( 1). -  
 , -  
 ). -

1

		I-II	III-IY	
		21 (70%)	9 (30%)	8 (27%)
		18 (60 %)	12 (40%)	8 (27%)
-		19 (63%)	11 (37%)	9 (30%)
		22 (73%)	8 (27%)	8 (27%)
		16 (53%)	14 (47%)	12 (40%)
		22 (73%)	8 (27%)	8 (27%)
		18 (60%)	12 (40%)	9 (30%)
		18 (60%)	12 (40%)	10 (33%)
		74 (62%)	46 (38%)	38 (32%)
		80 (75%)	40 (25%)	34 (28%)

-  
 -  
 ,  
 -  
 -  
 74 (62%) -  
 I-II -  
 -  
 III 9 (30%):  
 (IY : 3 1 - - 3, -  
 ) , , 30  
 -  
 3 (10%) :  
 , , - 1  
 « » -  
 (17%):  
 3, - 1,  
 - 1  
 ,  
 12  
 , 2 (6,7%) :  
 ,  
 4,2%.  
 12 ,  
 (40%): 22,5% (27 ).  
 6, - 3, -  
 - 2,  
 .

«  
»,  
8  
*C. trachomatis*.  
*Chlamydia psittaci*.  
U. urealyticum.  
[13].

76

11. Craft J.C., Siepmann N. Overview of the safety profile of clarithromycin suspension in pediatric patients. *Pediatr. Infect. Dis. J.*, 1993, 12: 142-147.

12. Kohno S., Koga H., Yamaguchi K., et al. A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires' disease. *J. Antimicrob. Chemother.*, 1989, 24: 397-405.

13. Ridgway G.L. Chlamydia and other sexually transmitted diseases. In: *New Macrolides, Azalides, and Streptogramins in Clinical Practice*. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 147-154.

14. Scaglione F., Demartini G., Fraschini F. Distribution of clarithromycin to intracellular and

extracellular sites of infection: an overview. In: *New Macrolides, Azalides, and Streptogramins in Clinical Practice*. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 380-385.

15. Takeda H., Miura H., Kawahira M., et al. Long-term administration study on TE-031 (A-56268) in treatment of diffuse panbronchiolitis. *Kansenshogaku Zasshi*, 1989, 63: 71-78.

16. Yokota T., Suzuki E., Arai T. TE-031 (A-56268), a new macrolide, its in vitro antibacterial activity, synergy of bactericidal effect with serum complement and mouse cultured macrophages, and incorporation into leucocytes. *Chemotherapy*, 1988, 36: 59-70.

[1, 4, 6].

5].

2,5% 38,2% [2, 3,